CARLSBAD, CALIFORNIA — Lineage Cell Therapeutics announced that its experimental ReSonance (ANP1) cell therapy program for hearing loss has completed the development activities planned for the first year of its research collaboration with William Demant Invest (WDI), allowing the project to advance into its second year....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is an early-stage preclinical milestone announcement with no human trial data; audiologists cannot apply this finding to current practice.
If cell-based auditory nerve regeneration ever reaches the clinic, it could represent a fundamentally different treatment paradigm for sensorineural hearing loss beyond conventional amplification or cochlear implants.
- 01Lineage Cell Therapeutics' ReSonance (ANP1) program targets auditory nerve repair using cell therapy.
- 02The program completed its planned first-year development milestones under a collaboration with William Demant Invest.
- 03No human clinical trials have been announced; the therapy remains in preclinical development.
- 04William Demant Invest's involvement signals major hearing-industry interest in biological hearing restoration.
- 05Auditory nerve regeneration, if successful, could eventually complement or reduce reliance on hearing aids and cochlear implants.
ReSonance (ANP1) has completed planned first-year development milestones.
press releaseunclearThe cell therapy is designed to restore auditory nerve function.
press releasepromotional